UBS Reiterates Buy Rating on Teva Pharma (TEVA) as Pipeline Opportunities Broaden
Tweet Send to a Friend
UBS analyst Ashwani Verma reiterated a Buy rating and $42.00 price target on Teva Pharma (NYSE: TEVA).The analyst commented, "We ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
